Group 1 - Nanjing Paitemei Biological Technology Co., Ltd. has successfully completed a new round of financing, with participation from Qinzhi Capital [3] - This marks the second time Paitemei has attracted capital since its establishment, with its first financing supported by Jiangbei New Area Science and Technology Investment Group, highlighting the area's ability to nurture quality pet pharmaceutical enterprises [5] - Paitemei focuses on innovative drug research and development for pets, aligning with the strategic layout of the pet health industry cluster in Jiangbei New Area [5] Group 2 - The company aims to create the first high-standard one-stop pet health innovation technology service platform in China, with over 10 ongoing projects, including 4 targeted innovative drug projects [5] - Paitemei's research and development capabilities are among the industry's top, addressing the gap in domestic pet innovative drugs and aligning with the region's goal of promoting the autonomy of pet pharmaceuticals [5] - Qinzhi Capital, established in October 2015, specializes in investments in the biopharmaceutical and healthcare sectors, focusing on innovative drugs, cell and gene therapy, and synthetic biology [7] Group 3 - Qinzhi Capital has actively invested in the pet medical sector, participating in projects such as pet vaccine company Hertz Life and Paitemei, with its Dongguan Science and Technology Qinzhi Pet Health Biomedicine Fund managing nearly 100 million yuan [7] - The firm emphasizes "returning investment to the real economy and capital serving the industry," aiming to empower invested companies through deep industry resource connections [7]

Core Viewpoint - The investment by Guanggu Chantuo in Wuhan Xindong Biotechnology Co., Ltd. marks a significant step in enhancing the capabilities of the pet pharmaceutical industry in China, focusing on innovative CRO services for pet drug development [1] Company Summary - Wuhan Xindong Biotechnology, established in 2023, specializes in providing evaluation services for pet drug development, offering a comprehensive R&D service solution that includes model animals, preclinical, and clinical research [1] - The funding will primarily be used for the expansion of experimental animal facilities and the continuous improvement of disease models and technology platforms [1] - The company aims to create a one-stop R&D service platform addressing core client pain points, enhancing R&D efficiency, reducing overall R&D costs, and accelerating the development and transformation of innovative pet drugs [1] Industry Summary - The investment is expected to promote the advancement of the domestic pet pharmaceutical industry, contributing to the establishment of a more vibrant life and health industry ecosystem in China [1]